Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...

CRISPR Therapeutics has two next generation approaches ... developed targeted conditioning program, an anti-CD117 (c-Kit) antibody-drug conjugate (ADC), through preclinical studies.

New strategies promise to streamline workflows, conserve consumables, increase productivity, and enhance reproducibility.

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

Collectively, emerging technologies are creating an unstable world, where we don’t clearly understand what national security ...

The tool segment is segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, chassis organisms ... range of products for the synthetic biology industry, such as CRISPR & Gene ...

The global synthetic biology market is anticipated to reach USD 31.52 billion in 2029 from USD 12.33 billion in 2024, with a ...